In fiscal year 2025, RPbio (314140) reported revenue of 136.2 billion KRW.
Income Statement
| Year | Revenue | Op Profit | Net Income | Source |
|---|---|---|---|---|
| 2025 | 136.2 billion KRW | 5.1 billion KRW | 4.7 billion KRW | [source] |
| 2024 | 124.0 billion KRW | -694 million KRW | -907 million KRW | [source] |
| 2023 | 151.0 billion KRW | 6.6 billion KRW | 5.4 billion KRW | [source] |
| 2022 | 138.1 billion KRW | 9.6 billion KRW | 4.3 billion KRW | [source] |
| 2021 | 115.0 billion KRW | 5.9 billion KRW | 3.8 billion KRW | — |
Balance Sheet
| Year | Total Assets | Total Liabilities | Total Equity | Source |
|---|---|---|---|---|
| 2025 | 156.3 billion KRW | 49.1 billion KRW | 107.2 billion KRW | [source] |
| 2024 | 159.5 billion KRW | 57.2 billion KRW | 102.3 billion KRW | [source] |
| 2023 | 166.2 billion KRW | 63.5 billion KRW | 102.7 billion KRW | [source] |
| 2022 | 173.2 billion KRW | 82.0 billion KRW | 91.1 billion KRW | [source] |
| 2021 | — | — | — | — |
Years without a source link are outside the DART financial API collection period.
Balance sheet figures for the relevant year were not collected.